November 1st, 2021
Whiz Partners Inc.
Whiz Partners Established a New Company to Generate Composition of Matter Patents for New Chemical Entities
and Contribute to the R&D of Pharmaceutical Companies
Whiz Partners Inc. (Minato-ku Tokyo, Japan, Atsushi Matsumura President & CEO, hereinafter “WhizPartners”) established IP Generator Inc. (Minato-ku, Tokyo, Japan, Satoru Iino, President & CEO, hereinafter"IPG") as a wholly owned subsidiary of the Healthcare New Platform Fund Limited Partnership, where WhizPartners has been the general partner. IPG will generate composition of matter patents for new chemical entities
by conducting non-clinical research and development activities and make variety of transactions mainly withpharmaceutical companies.
IPG will enter into a comprehensive business alliance with Axcelead and its subsidiary Axcelead Drug DiscoveryPartners (hereinafter "ADDP"), where ADDP has taken over about 200 promising drug seeds inherited fromTakeda Pharmaceutical Company Limited (hereinafter “Takeda”). IPG will prioritize and select non-clinicalresearch projects from ADDP’s promising drug seeds and a wide range of pharmaceutical companies and conduct
non-clinical research activities by itself. Then, IPG will acquire composition of matter patents for new chemical
entities and license out them to pharmaceutical companies. Utilizing IPG may lead pharmaceutical companies tobe able to continuously replenish their R&D pipelines and accelerate the horizontal division of labor model, whichis expected to have a significant positive impact on the efficiency of R&D activities. There is no capital
relationship between IPG and the Axcelead Group.
In the pharmaceutical industry, we believe that the number of companies promoting business based on theconcept of personalized medicine will increase in the future. As a result, IPG will become a new platform
company in the pharmaceutical industry, as it enables the efficient creation of a large number of new drugcandidates and the penetration of R&D strategies aimed at delivering small quantities of a wide variety of drugs topeople in line with their individual needs. We believe that the ecosystem promoted by IPG will become a systemthat contributes to society by reducing healthcare costs in many countries.
【Outline of the company】
Name of the Company

IP Generator Inc.

Location

2-5-1 Atago, Minato-ku, Tokyo 105-6236

Investor

Healthcare New Platform Fund（100％）
General Partner; Whiz Partners Inc.

Capital and Capital Reserves

10 million JPY

Established

October 26th, 2021

(1) R&D and sales of pharmaceuticals(2) Business in increasing the value of intellectual property and selling usage
Business Scoperights(3) All other businesses incidental and related to the above
President CEO

Satoru Iino

Board of directors Tatsuya Yamada
Management

Board of directors Yuki Hasegawa
AuditorTakashi Yamaguchi

About Whiz Partners Inc.
Whiz Partners Inc. (Tokyo, Japan) is an alternative asset management firm with Growth Equity and Global
Macro Hedge fund offerings. Whiz Partners has a strong track record, not only in Healthcare investments but also
in information technology and AI. For more information about Whiz Partners, please visit their website
http://www.whizp.com/e/
About Healthcare New Platform Fund
Healthcare New Platform Fund is planning to invest mainly in new healthcare platform companies, such as“Axcelead, Inc.”, the first healthcare platform company in Japan, and CDMO company “ARCALIS, Inc.” which
will build a Japan’s first and only plant of APIs and formulations for mRNA drugs and vaccines in Minami-soma,Fukushima. For further information, please refer to the press release (http://www.whizp.com/wpcontent/uploads/2021/10/1906_01.pdf)

Contact: Eri Yokota yokota@whizp.com